Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 87

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 87
---
(48,098)
  
    Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. 
    $(7,947,107) 
    $(3,765,702)

48

The following table sets forth our results of
operations as a percentage of revenue:

    For the Year Ended
    December 31, 
  
    Consolidated Statements of Operations Data: 
    2024  
    2023 
  
    Product Revenues – net of Discounts and Rebates 
     100.00% 
     100.00%
  
    Cost of Revenues 
     63.33  
     187.15 
  
    Gross Profit (Loss) 
     36.67  
     (87.15)
  
    Research Revenues 
     12.14  
     - 
  
    Net Revenue (Loss) 
     48.81  
     (87.15)

    Operating Expenses: 

    Research and Development 
     820.73  
     272.81 
  
    General and Administrative Expenses 
     827.06  
     1,672.83 
  
    Total Operating Expenses 
     1,647.78  
     1,945.64 

    Loss from Operations 
     (1,598.97) 
     (2,032.78)

    Interest Expense 
     (1.30) 
     (901.77)
  
    Derivative Expense 
     -  
     (157.64)
  
    Change in Fair Value of Derivative Liabilities 
     274.20  
     (14.70)
  
    Loss on Debt Extinguishment 
     -  
     (485.65)
  
    Change in Fair Value of Promissory Note 
     -  
     2,121.39 
  
    Other Income (Expense), net 
     16.70  
     (32.78)
  
    Total Interest and Other Income (Expense), net 
     289.60  
     528.85 
  
    Loss from Operations before Provision for Income Taxes 
     (1,309.37) 
     (1,503.93)
  
    Provision for Income Taxes (Note 9) 
     0.04  
     0.10 
  
    Net Loss including Noncontrolling Interest